Intravenous cholecystokinin-tetrapeptide (CCK-4) administration reliably and dose-dependently provokes panic anxiety in man, accompanied by adrenocorticotropic hormone (ACTH) and cortisol release. Preclinical findings suggest that behavioral and endocrine effects of CCK-4 are mediated via corticotro...
Intravenous cholecystokinin-tetrapeptide (CCK-4) administration reliably and dose-dependently provokes panic anxiety in man, accompanied by adrenocorticotropic hormone (ACTH) and cortisol release. Preclinical findings suggest that behavioral and endocrine effects of CCK-4 are mediated via corticotropin-releasing hormone (CRH) release. Anxiogenic stimulation of the central CCK-receptors in man was shown to increase as well vasopressin (AVP), which acts synergistically with CRH as pituitary-adrenocortical axis stimulator during stress. Copeptin (CoP), the C-terminal part of pre-pro-AVP, is released in an equimolar ratio to AVP. It is more stable in the circulation and easier to determine than AVP and it was found to closely mirror the production of AVP. So far, CoP secretion has not been characterized during panic provocation. In 30 healthy male human subjects, we repeatedly measured CoP in plasma during a panic challenge and studied its correlation to Acute Panic Inventory (API) ratings and plasma ACTH and cortisol. CoP levels correlated positively with the increase in API ratings (r=0.41, p=0.03), while ACTH or cortisol did not (r=0.08, p=0.68 and r=0.12, p=0.53, respectively). CoP levels correlated also positively with ACTH (r=0.48, p=0.009) and cortisol (r=0.48, p=0.01) concentrations throughout the CCK-4 challenge. As expected, we found a positive correlation between plasma ACTH and cortisol levels (r=0.57, p=0.001). A vasopressinergic activation during CCK-4 induced panic was demonstrated, which was correlated positively to panic symptoms and pituitary-adrenocortical release. Our findings suggest a role of CoP as a potential surrogate marker of CCK-4 panic symptoms. Further studies are needed to replicate our results and to further clarify the role of CoP as a stress-sensitive hormone in different panic paradigms as well as in panic patients.
Intravenous cholecystokinin-tetrapeptide (CCK-4) administration reliably and dose-dependently provokes panic anxiety in man, accompanied by adrenocorticotropic hormone (ACTH) and cortisol release. Preclinical findings suggest that behavioral and endocrine effects of CCK-4 are mediated via corticotropin-releasing hormone (CRH) release. Anxiogenic stimulation of the central CCK-receptors in man was shown to increase as well vasopressin (AVP), which acts synergistically with CRH as pituitary-adrenocortical axis stimulator during stress. Copeptin (CoP), the C-terminal part of pre-pro-AVP, is released in an equimolar ratio to AVP. It is more stable in the circulation and easier to determine than AVP and it was found to closely mirror the production of AVP. So far, CoP secretion has not been characterized during panic provocation. In 30 healthy male human subjects, we repeatedly measured CoP in plasma during a panic challenge and studied its correlation to Acute Panic Inventory (API) ratings and plasma ACTH and cortisol. CoP levels correlated positively with the increase in API ratings (r=0.41, p=0.03), while ACTH or cortisol did not (r=0.08, p=0.68 and r=0.12, p=0.53, respectively). CoP levels correlated also positively with ACTH (r=0.48, p=0.009) and cortisol (r=0.48, p=0.01) concentrations throughout the CCK-4 challenge. As expected, we found a positive correlation between plasma ACTH and cortisol levels (r=0.57, p=0.001). A vasopressinergic activation during CCK-4 induced panic was demonstrated, which was correlated positively to panic symptoms and pituitary-adrenocortical release. Our findings suggest a role of CoP as a potential surrogate marker of CCK-4 panic symptoms. Further studies are needed to replicate our results and to further clarify the role of CoP as a stress-sensitive hormone in different panic paradigms as well as in panic patients.
Am. J. Psychiatry Bradwejn 151 261 1994 10.1176/ajp.151.2.261 Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients
Neuroendocrinology Calogero 58 71 1993 10.1159/000126514 Effects of cholecystokinin octapeptide on the hypothalamic-pituitary-adrenal axis function and on vasopressin, prolactin and growth hormone release in humans
Nat. Rev. Endocrinol. Christ-Crain 12 168 2016 10.1038/nrendo.2015.224 Copeptin in the diagnosis of vasopressin-dependent disorders of fluid homeostasis
World J. Biol. Psychiatry Demiralay 13 526 2012 10.3109/15622975.2011.604351 Differential effects to CCK-4-induced panic by dexamethasone and hydrocortisone
J. Clin. Endocrinol. Metab. Hensen 66 668 1988 10.1210/jcem-66-4-668 Effects of incremental infusions of arginine vasopressin on adrenocorticotropin and cortisol secretion in man
Clin. Endocrinol. Kacheva 82 570 2015 10.1111/cen.12608 Gender-specific co-activation of arginine vasopressin and the hypothalamic-pituitary-adrenal axis during stress
Neuro Endocrinol. Lett. Katan 29 341 2008 Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level
Dialogues Clin. Neurosci. Kellner 13 485 2011 10.31887/DCNS.2011.13.4/mkellner Experimental panic provocation in healthy man-a translational role in anti-panic drug development?
Peptides Le Melledo 22 1349 2001 10.1016/S0196-9781(01)00462-4 Arginine-vasopressin and oxytocin response to cholecystokinin-tetrapeptide
J. Clin. Endocrinol. Metab. Miaskiewicz 68 837 1989 10.1210/jcem-68-4-837 Neurohypophyseal secretion in response to cholecystokinin but not meal-induced gastric distention in humans
J. Clin. Psychiatry Sheehan 59 Suppl. 20 22 1998 The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10
Eur. J. Endocrinol./Eur. Fed. Endocr. Soc. Siegenthaler 171 737 2014 10.1530/EJE-14-0405 Copeptin concentrations during psychological stress: the PsyCo study
Psychoneuroendocrinology Spanakis 63 254 2016 10.1016/j.psyneuen.2015.10.009 Association of HPA axis hormones with copeptin after psychological stress differs by sex
J. Psychiatr. Res. Stroehle 43 1013 2009 10.1016/j.jpsychires.2009.02.004 The acute antipanic and anxiolytic activity of aerobic exercise in patients with panic disorder and healthy control subjects
Stress (Amsterdam, Netherlands) Urwyler 18 134 2015 10.3109/10253890.2014.993966 Copeptin as a stress marker prior and after a written examination - the CoEXAM study
※ AI-Helper는 부적절한 답변을 할 수 있습니다.